AI news impact · China A-shares
GemPharmatech Co., Ltd. Class A (688046) news impact
On 2026-11-12 Wave Radar's AI rated the news on GemPharmatech Co., Ltd. Class A as major positive (impact score +65%).
GemPharmatech reported Q1-Q3 2026 net profit of 170 million yuan (+54.79% YoY) and saw net margin purchases exceeding 10 million yuan.
- Direction
- Major positive
- Impact score
- +65%
- Confidence
- 85%
- Headlines read
- 5
- Date
- 2026-11-12
AI assessment
A 54.79% YoY net profit surge in Q1-Q3 demonstrates robust operational profitability and strong growth momentum.
Sector impact
Provides positive earnings sentiment for the laboratory animal models and life sciences tools sector.
Headlines the AI read
- 科创板股融资融券余额每日变动(11月9日) AkShare/证券时报网 · 2026-11-10
- 59只科创板股获融资净买入超1000万元 AkShare/证券时报网 · 2026-11-10
- 科创板股融资融券余额每日变动(11月3日) AkShare/证券时报网 · 2026-11-04
- 41只科创板股融资余额增加超500万元 AkShare/证券时报网 · 2026-11-04
- 药康生物:2026年前三季度净利润1.7亿元 同比增长54.79% AkShare/中国证券报·中证网 · 2026-10-28
Rating history
One rating per trading day the stock was covered.
More on GemPharmatech Co., Ltd. Class A
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.